About
Osteoarthritis (OA) is one of the most common musculoskeletal diseases, with an estimated prevalence of 12% to 22% worldwide. It is the leading cause of disability among older adults, with an estimated lifetime risk of knee OA about 40% in men and 47% in women.
Clinical trials seek to determine whether treatments are safe and beneficial for patients by comparing their relative effects on outcomes chosen to identify benefit or harm. The results can then be used to make decisions on whether a treatment under investigation should be recommended. It is, therefore, essential that outcomes reported in trials are those needed by decision makers, and reflect meaningful measures for patients, clinicians, and others.
OMERACT Scientific Public–Private Partnerships: PROACTIVE
OMERACT participates in PROACTIVE, a public private, pre-competitive consortium focused on developing regulator-aligned outcome measures for osteoarthritis (OA) clinical trials. PROACTIVE brings together academia, industry, government agencies including FDA CDER participants, patient organizations, and professional societies to share data, expertise, and innovative thinking around symptom, function, and structural outcome measurement in OA.
The consortium is working to address key scientific and regulatory challenges in OA drug development, including defining meaningful disease progression, identifying reliable structural and symptom-based endpoints, and evaluating potential surrogate markers to support therapies aimed at slowing OA progression.
A full description of the consortium’s mission, governance, FDA engagement, and methodology activities is available here: Learn more about PROACTIVE
Current Stage in the OMERACT Process
Building on established domains, the group is reviewing instruments that best reflect pain, function, and quality of life. These evaluations will guide instrument selection for use in trials.
Meet the Team
Phil Conaghan, UK
Chair
Lee Simon, USA
Chair
OMERACT Endorsed Core Domain Set for Hip & Knee Osteoarthritis
